NRx Pharmaceuticals, Inc. NRXP
Regular-session close
After hours · Nov 20, 7:58 PM ET
- YTD
- -20.66%
- 1 year
- +5.91%
Held by funds
8 US ETFs and mutual funds hold NRXP · largest positions
Ownership
- Institutions 6.05%
- Insiders 23.6%
- Public and other holders 70.4%
Top institutional holders
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 1.99% | 240,316 | 341.25K | Sep 29, 2024 |
| Anson Funds Management LP | 1.18% | 142,525 | 202.38K | Sep 29, 2024 |
| AdvisorShares Investments, LLC | 1.08% | 130,085 | 184.72K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.64% | 77,341 | 109.82K | Sep 29, 2024 |
| Sabby Management, LLC | 0.29% | 35,049 | 49.77K | Sep 29, 2024 |
| Blackrock Inc. | 0.24% | 29,075 | 41.29K | Sep 29, 2024 |
Top mutual fund holders
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AdvisorShares Trust-AdvisorShares Psychedelics ETF | 2.41% | 291,271 | 413.60K | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 1.60% | 193,423 | 274.66K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.39% | 46,893 | 66.59K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.36% | 43,510 | 61.78K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.09% | 10,327 | 14.66K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.08% | 10,005 | 14.21K | Oct 30, 2024 |
Included in Plus and up
Sign in to see Institutional ownership
How much funds own from their 13F filings, quarter by quarter, and the largest holders.
Free with an account
Sign in to see Insider activity
Two years of insider buying and selling by month, marked on the price.
Included in Plus and up
Sign in to see Congress trading
Every stock trade disclosed by members of the US Senate and House.
Leadership team
Who runs NRXP, and what each was last paid
Jonathan C. Javitt, Co-Founder, Chairman & CEOAverage age 67
| Name | Title | Pay | Age |
|---|---|---|---|
| Jonathan C. Javitt | Co-Founder, Chairman & CEO | $718K | 69 |
| Michael S. Abrams | CFO & Treasurer | $363K | 56 |
| Riccardo Panicucci | Chief Manufacturing & Technology Officer | $240K | 64 |
| Dennis K. McBride | Chief Strategy Officer & Director | $38.5K | 72 |
| Joseph Casper | Chief Operating Officer | — | 75 |
| Michael Taylor | Chief Development Officer & Director | — | 51 |
| Hervé Perron | Chief Scientist | — | 67 |
| Philip T. Lavin | Chief Methodologist | — | 79 |
| Glenn Tyson | Chief Commercial Officer | — | — |
| Joshua C. Brown | Chief Medical Innovation Officer | — | — |
| Suzanne Messere | Investor Relations | — | — |
Pay is the latest total FMP has for each person (salary, bonus, stock and other awards) and can lag the newest proxy statement. Source: Financial Modeling Prep, from the company’s SEC filings.
Free with an account
Sign in to see CEO compensation
What the chief executive was paid each year, by salary, bonus and stock, beside the company's earnings.
Free with an account
Sign in to see Board of directors
Who sits on the board, who chairs it, and how long each director has served.
Insiders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GOROVITZ AARON | Director | Purchase | Aug 29, 2023 | 0 |
| HURVITZ CHAIM | Director | Purchase | Aug 29, 2023 | 2,214,790 |
| JAVITT JONATHAN C | Chairman of the Board | Purchase | Dec 16, 2024 | 1,516,830 |
